Philip Herman Net Worth

Philip Herman biography

Philip Herman serves as Senior Vice President and Chief Commercial Officer of the Company. Mr. Herman joined our Company in June 2018 as Vice President and Chief Commercial Officer and since January 1, 2020 has been Senior Vice President and Chief Commercial Officer. Mr. Herman brings extensive commercial experience with a focus in oncology and rare diseases. He has a proven track record of commercial success, including launch and sales attainment across the full product life cycle. Previous positions include VP, Head of Santhera U.S. and Head of Commercial, Head of Marketing at Dyax Corp., Director of Marketing at Vanda Pharmaceuticals, and various commercial positions of increasing responsibility at Pfizer. Mr. Herman received his MBA from the Kellogg School of Management at Northwestern University.

How old is Philip Herman?

Philip Herman is 41, he's been the Senior Vice President and Chief Commercial Officer of Y-Mabs Therapeutics Inc since 2020. There are 18 older and no younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.

What's Philip Herman's mailing address?

Philip's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE SUITE 3350, NEW YORK, NY, 10169.

Insiders trading at Y-Mabs Therapeutics Inc

Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad y Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.

What does Y-Mabs Therapeutics Inc do?

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Y-Mabs Therapeutics Inc executives and stock owners

Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
  CEO & Director
• Claus Moller-San Pedro,
  Chief Executive Officer, Director
• Thomas Gad,
  Chairman of the Board, President, Founder, Head of Business Development and Strategy
• Thomas Gad,
  Founder, Chairman, Pres and Head of Bus. Devel. & Strategy
• Bo Kruse,
  Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
• Bo Kruse,
  Exec. VP, Sec., Treasurer & CFO
• David Gill,
  Independent Director
• James Healy,
  Independent Director
• Ashutosh Tyagi,
  Independent Director
• Gerard Ber,
  Independent Director
• Johan Wedell-Wedellsborg,
  Independent Director
• Torben Lund-Hansen,
  Senior Vice President, Chief Technical Officer
• Steen Lisby,
  Senior Vice President, Chief Medical Officer
• Philip Herman,
  Senior Vice President and Chief Commercial Officer
• Mahiuddin Ahmed,
  Senior Vice President, Chief Scientific Officer
• Joris Wilms,
  Chief Operating Officer, Senior Vice President
• Sue Smith,
  Sr. VP & Chief Commercial Officer
• Dr. Torben Lund-Hansen,
  Sr. VP & Chief Technical Officer
• Joris Wiel Jan Wilms,
  Sr. VP & COO
• Dr. Vignesh Rajah,
  Sr. VP & Chief Medical Officer
• Dr. Steen Lisby M.D., M.Sc.,
  Sr. VP & Chief Scientific Officer
• Peter P. Pfreundschuh,
  CFO and Treasurer
• Gregory S Raskin,
  Director
• Ashu Tyagi,
  Director
• Mary Tagliaferri,
  Director
• Laura Hamill,
  Director
• Vignesh Rajah,
  SVP & CHIEF MEDICAL OFFICER
• Biotech Ap S Wg,
  Director
• Susan Laura Smith,
  SVP & CHIEF COMMERCIAL OFFICER
• Michael J Rossi,
  PRESIDENT & CEO